NO315074B1 - Anvendelse av flupirtin for fremstilling av legemidler for behandling av indusert apoptotisk celledöd av lymfocytter - Google Patents

Anvendelse av flupirtin for fremstilling av legemidler for behandling av indusert apoptotisk celledöd av lymfocytter Download PDF

Info

Publication number: NO315074B1
Authority: NO; Norway
Prior art keywords: flupirtine; cells; lymphocytes; treatment; hiv
Prior art date: 1995-11-07

Application number

NO19981898A

Other languages

English (en)

Norwegian (no)

Other versions

NO981898L (no

NO981898D0 (no

Inventor

Gabriela Pergande

Werner E G Mueller

Original Assignee

Viatris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-07

Filing date

1998-04-27

Publication date

2003-07-07

1998-04-27 Application filed by Viatris Gmbh filed Critical Viatris Gmbh

1998-04-27 Publication of NO981898L publication Critical patent/NO981898L/no

1998-04-27 Publication of NO981898D0 publication Critical patent/NO981898D0/no

2003-07-07 Publication of NO315074B1 publication Critical patent/NO315074B1/no

Links

JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title claims abstract description 52
229960003667 flupirtine Drugs 0.000 title claims abstract description 51
210000004698 lymphocyte Anatomy 0.000 title claims abstract description 20
238000011282 treatment Methods 0.000 title claims abstract description 15
239000003814 drug Substances 0.000 title claims abstract description 12
230000006907 apoptotic process Effects 0.000 title claims description 35
229940079593 drug Drugs 0.000 title abstract description 8
238000004519 manufacturing process Methods 0.000 title description 2
208000030507 AIDS Diseases 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims description 6
239000013543 active substance Substances 0.000 claims description 2
210000004027 cell Anatomy 0.000 abstract description 63
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
201000010099 disease Diseases 0.000 abstract description 12
238000002560 therapeutic procedure Methods 0.000 abstract description 3
238000011321 prophylaxis Methods 0.000 abstract description 2
230000006735 deficit Effects 0.000 abstract 1
108010093894 Xanthine oxidase Proteins 0.000 description 19
102100033220 Xanthine oxidase Human genes 0.000 description 18
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 18
230000001640 apoptogenic effect Effects 0.000 description 10
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 9
241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
238000011534 incubation Methods 0.000 description 7
230000000694 effects Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
238000011835 investigation Methods 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 4
108700012813 7-aminoactinomycin D Proteins 0.000 description 4
208000014644 Brain disease Diseases 0.000 description 4
108091006146 Channels Proteins 0.000 description 4
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
208000032274 Encephalopathy Diseases 0.000 description 4
238000003556 assay Methods 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
238000013467 fragmentation Methods 0.000 description 3
238000006062 fragmentation reaction Methods 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010049816 Muscle tightness Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
238000009826 distribution Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
239000003158 myorelaxant agent Substances 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229960001655 flupirtine maleate Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000002687 intercalation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
230000000631 nonopiate Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Polyurethanes Or Polyureas (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO19981898A 1995-11-07 1998-04-27 Anvendelse av flupirtin for fremstilling av legemidler for behandling av indusert apoptotisk celledöd av lymfocytter NO315074B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19541405A DE19541405A1 (de)	1995-11-07	1995-11-07	Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
PCT/DE1996/002009 WO1997017072A2 (de)	1995-11-07	1996-10-23	Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen

Publications (3)

Publication Number	Publication Date
NO981898L NO981898L (no)	1998-04-27
NO981898D0 NO981898D0 (no)	1998-04-27
NO315074B1 true NO315074B1 (no)	2003-07-07

Family

ID=7776799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981898A NO315074B1 (no)	1995-11-07	1998-04-27	Anvendelse av flupirtin for fremstilling av legemidler for behandling av indusert apoptotisk celledöd av lymfocytter

Country Status (26)

Country	Link
US (2)	US6034111A (da)
EP (1)	EP0859613B1 (da)
JP (1)	JPH11514652A (da)
KR (1)	KR100512673B1 (da)
CN (1)	CN1116037C (da)
AT (1)	ATE316789T1 (da)
AU (1)	AU711207B2 (da)
BG (1)	BG63149B1 (da)
BR (1)	BR9611588A (da)
CA (1)	CA2189705C (da)
CZ (1)	CZ298115B6 (da)
DE (2)	DE19541405A1 (da)
DK (1)	DK0859613T3 (da)
ES (1)	ES2257755T3 (da)
HU (1)	HU225742B1 (da)
MX (1)	MX9803610A (da)
NO (1)	NO315074B1 (da)
NZ (1)	NZ330414A (da)
PL (1)	PL186537B1 (da)
PT (1)	PT859613E (da)
RU (1)	RU2200555C2 (da)
SK (1)	SK284601B6 (da)
TW (1)	TW393317B (da)
UA (1)	UA51682C2 (da)
WO (1)	WO1997017072A2 (da)
ZA (1)	ZA968783B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19625582A1 (de) *	1996-06-27	1998-01-02	Asta Medica Ag	Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en)	1999-12-01	2004-11-23	Duke University	Method of treating batten disease
DE10327674A1 (de)	2003-06-20	2005-01-05	Awd.Pharma Gmbh & Co. Kg	Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (en) *	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20080279930A1 (en) *	2007-05-07	2008-11-13	Bernd Terhaag	Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) *	2009-05-29	2011-07-07	Corden PharmaChem GmbH, 68305	Verfahren zur Herstellung von Flupirtin
US9212416B2 (en) *	2009-08-07	2015-12-15	Swagelok Company	Low temperature carburization under soft vacuum
DE102010030053A1 (de)	2010-06-14	2011-12-15	Awd.Pharma Gmbh & Co.Kg	Injizierbare Darreichungsform von Flupirtin
JP2015508789A (ja) *	2012-03-02	2015-03-23	メダファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	医薬製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN172468B (da) *	1990-07-14	1993-08-14	Asta Medica Ag
DE4327516A1 (de) *	1993-08-17	1995-02-23	Asta Medica Ag	Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

1995
- 1995-11-07 DE DE19541405A patent/DE19541405A1/de not_active Ceased
1996
- 1996-10-18 ZA ZA968783A patent/ZA968783B/xx unknown
- 1996-10-23 JP JP9517734A patent/JPH11514652A/ja active Pending
- 1996-10-23 HU HU9901659A patent/HU225742B1/hu not_active IP Right Cessation
- 1996-10-23 RU RU98111152/14A patent/RU2200555C2/ru not_active IP Right Cessation
- 1996-10-23 WO PCT/DE1996/002009 patent/WO1997017072A2/de not_active Ceased
- 1996-10-23 CN CN96198131A patent/CN1116037C/zh not_active Expired - Fee Related
- 1996-10-23 KR KR10-1998-0703376A patent/KR100512673B1/ko not_active Expired - Fee Related
- 1996-10-23 PT PT96945822T patent/PT859613E/pt unknown
- 1996-10-23 PL PL96326629A patent/PL186537B1/pl not_active IP Right Cessation
- 1996-10-23 CZ CZ0128398A patent/CZ298115B6/cs not_active IP Right Cessation
- 1996-10-23 BR BR9611588A patent/BR9611588A/pt not_active Application Discontinuation
- 1996-10-23 ES ES96945822T patent/ES2257755T3/es not_active Expired - Lifetime
- 1996-10-23 SK SK586-98A patent/SK284601B6/sk not_active IP Right Cessation
- 1996-10-23 DK DK96945822T patent/DK0859613T3/da active
- 1996-10-23 UA UA98062946A patent/UA51682C2/uk unknown
- 1996-10-23 EP EP96945822A patent/EP0859613B1/de not_active Expired - Lifetime
- 1996-10-23 AU AU17165/97A patent/AU711207B2/en not_active Ceased
- 1996-10-23 NZ NZ330414A patent/NZ330414A/en unknown
- 1996-10-23 AT AT96945822T patent/ATE316789T1/de active
- 1996-10-23 DE DE59611327T patent/DE59611327D1/de not_active Expired - Lifetime
- 1996-11-04 TW TW085113437A patent/TW393317B/zh not_active IP Right Cessation
- 1996-11-06 CA CA002189705A patent/CA2189705C/en not_active Expired - Fee Related
- 1996-11-07 US US08/744,953 patent/US6034111A/en not_active Expired - Lifetime
1998
- 1998-04-16 US US09/061,099 patent/US6034112A/en not_active Expired - Lifetime
- 1998-04-24 BG BG102404A patent/BG63149B1/bg unknown
- 1998-04-27 NO NO19981898A patent/NO315074B1/no not_active IP Right Cessation
- 1998-05-07 MX MX9803610A patent/MX9803610A/es not_active IP Right Cessation

Also Published As

Publication number	Publication date
TW393317B (en)	2000-06-11
HU225742B1 (en)	2007-07-30
BR9611588A (pt)	1999-04-06
ZA968783B (en)	1997-05-27
KR100512673B1 (ko)	2005-12-09
NO981898L (no)	1998-04-27
DE19541405A1 (de)	1997-05-15
SK284601B6 (sk)	2005-07-01
KR19990067366A (ko)	1999-08-16
NZ330414A (en)	1999-10-28
CZ298115B6 (cs)	2007-06-27
BG102404A (en)	1998-12-30
DE59611327D1 (de)	2006-04-13
HK1016508A1 (en)	1999-11-05
UA51682C2 (uk)	2002-12-16
JPH11514652A (ja)	1999-12-14
MX9803610A (es)	1998-09-30
CN1116037C (zh)	2003-07-30
WO1997017072A3 (de)	1997-07-24
NO981898D0 (no)	1998-04-27
CA2189705A1 (en)	1997-05-08
US6034111A (en)	2000-03-07
CN1201391A (zh)	1998-12-09
CZ128398A3 (cs)	1998-09-16
ATE316789T1 (de)	2006-02-15
RU2200555C2 (ru)	2003-03-20
AU711207B2 (en)	1999-10-07
WO1997017072A2 (de)	1997-05-15
EP0859613A2 (de)	1998-08-26
HUP9901659A3 (en)	2001-04-28
DK0859613T3 (da)	2006-06-06
HUP9901659A2 (hu)	1999-09-28
PT859613E (pt)	2006-06-30
BG63149B1 (bg)	2001-05-31
SK58698A3 (en)	1998-09-09
ES2257755T3 (es)	2006-08-01
US6034112A (en)	2000-03-07
PL326629A1 (en)	1998-10-12
PL186537B1 (pl)	2004-01-30
AU1716597A (en)	1997-05-29
EP0859613B1 (de)	2006-02-01
CA2189705C (en)	2005-08-09

Legal Events

Date	Code	Title	Description
2014-05-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DE3650377T2 (de)	1996-02-22	Regulierung der retroviralen replikation, infektion und pathogenese.
CA2373883A1 (en)	2001-01-11	Method of reducing neuronal injury or apoptosis
Crowe	1995	Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection
US6034111A (en)	2000-03-07	Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
JPH09505804A (ja)	1997-06-10	抗ウイルス剤としてのフラビン誘導体
WO1997017072A9 (de)	1997-08-21	Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
KR102873128B1 (ko)	2025-10-17	운동 뉴런 질환 및 신경근 접합 장애 치료를 위한 N-(3-(4-(3-(다이이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민 황산염 및 이의 용매화물의 용도
EP1075270B1 (en)	2005-06-15	Short peptide for treatment of neurological degenerative diseases
KR20230050363A (ko)	2023-04-14	질환의 치료에 있어서 btk 저해제의 용도
EP0555302A1 (en)	1993-08-18	Method of treating demyelinating disease
EP0624093A1 (en)	1994-11-17	The use of a compound for the manufacture of a medicament for the treatment of hiv infection
JPH11510803A (ja)	1999-09-21	免疫調節剤としての脂環式ジアミンの使用
Hedstrom et al.	1997	The effect of cocaine on mitogen-induced lymphyocyte proliferation in pregnant women
WO2000041547A2 (en)	2000-07-20	Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
NZ242264A (en)	1995-02-24	Polyadenylic acid/polyuridylic acid complexes in pharmaceutical compositions
JPH04225919A (ja)	1992-08-14	Ｃｄ４決定因子の発現および機能の選択的変調